• Vaccine Name: Marburg virus-like particles
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004117
• Type: Subunit vaccine
• Antigen: MARV or EBOV VP40 and GP (Warfield et al., 2004).
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• VP40 gene engineering:
  • Type: Recombinant protein preparation
  • Description: An RNA replicon based on VEEV was used as the vector, with the VEE structural genes replaced by VP40. VP40 seems to serve as a matrix protein, affecting interactions between the nucleoprotein complex and lipid membrane. It is also the most abundant part of the virion (Hevey et al., 1998).
    
    
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001238
  • Description: 200 μl of RIBI adjuvant was used (Warfield et al., 2004).
• Preparation: To generate mVLPs, 293T cells were co-transfected with pWRG 7077 vectors encoding for MARV VP40 and GP using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). To purify the VLPs, the cell supernatants were cleared from cellular debris and subsequently pelleted at 9500×g for 4 h. The crude VLP preparations were then separated on a 20â��60% continuous sucrose gradient centrifuged. The VLPs were concentrated by a second centrifugation and resuspended in endotoxin-free phosphate-buffered saline (PBS) (Warfield et al., 2004).
• Virulence: Guinea pigs that were vaccinated with inactivated MARV or mVLPs developed MARV-specific antibody titers(Warfield et al., 2004).

Guinea pig Response

• Host Strain: Strain 13
• Vaccination Protocol: Guinea pigs were vaccinated intramuscularly with 50 μg of mVLPs, eVLPs, or iMARV with 200 μl of RIBI monophosphoryl lipid+synthetic trehalose dicorynomycolate+cell wall skeleton emulsion diluted in endotoxin-free PBS (Warfield et al., 2004).
• Persistence: None noted.
• Immune Response: Both inactivated MARV and mVLP induced maximal humoral responses to MARV after only two vaccinations (Warfield et al., 2004) .
• Side Effects: Not noted.
• Challenge Protocol: Thirty days after the third vaccination, the guinea pigs were challenged subcutaneously with 1000 plaque-forming units (pfu) or 2000 LD50 of guinea pig-adapted MARV diluted in PBS [18](Warfield et al., 2004).
• Efficacy: Strong filovirus-specific antibody responses correlate with vaccine protective efficacy in guinea pigs(Warfield et al., 2004).